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Abstract
Background: For accuracy of quantitative reverse transcriptase-polymerase chain reaction (qRT-
PCR), normalisation with suitable reference genes is required. To date, no reference genes have
been validated for expression studies of bronchoalveolar (BAL) cells. The aims of this study were
to identify gene(s) with stable mRNA expression in BAL cells irrespective of gender, smoking, BAL
cellular composition, lung pathology, treatment; and to assess the influence of reference genes on
target gene expression data.
Results:  The mRNA expression of ten housekeeping genes (ACTB, ARF1, CANX, G6PD,
GAPDH, GPS1, GNB2L1, PSMB2, PSMD2, RPL32) was investigated by qRT-PCR in BAL cells from
71 subjects across a spectrum of lung diseases. The analyses were validated in an independent BAL
cohort from 63 sarcoidosis patients and 17 control subjects. A second derivative method was used
to calculate expression values (CTt); an equivalence test, applets BestKeeper, geNorm and
NormFinder were applied to investigate gene expression stability. Of the investigated genes,
PSMB2 (CTt ± SD, 23.66 ± 0.86) and RPL32 (18.65 ± 0.92) were the most stable; both were
constantly expressed in BAL samples from parallel investigated cohorts irrespective of evaluated
variables. Finally, to demonstrate effect of traditional (ACTB/GAPDH) and novel (PSMB2/RPL32)
reference genes as denominators, expression of two cytokines known associated with sarcoidosis
was investigated in sarcoid BAL cells. While normalization with PSMB2/RPL32 resulted in elevated
IFNG mRNA expression (p = 0.004); no change was observed using GAPDH/ACTB (p > 0.05).
CCL2 mRNA up-regulation was observed only when PSMB2/RPL32 were used as denominators (p
< 0.03).
Conclusion: PSMB2 and RPL32 are, therefore, suitable reference genes to normalize qRT-PCR in
BAL cells in sarcoidosis, and other interstitial lung disease.
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Background
Quantitative reverse transcriptase-polymerase chain reac-
tion (qRT-PCR) has become a method of choice for gene
expression studies in clinical samples, especially for low
copy targets of interest and for samples of limited size [1-
3]. In comparison to microarrays [4], qRT-PCR benefits
from broad dynamic range, sensitivity, and enables accu-
rate quantification [5,6].
However, to precisely quantify changes in expression level
of target genes by qRT-PCR, one must apply normalisa-
tion for heterogeneity in clinical samples and also for var-
iability introduced during RNA extraction and cDNA
synthesis [1,7]. Besides normalisation to sample size and
total RNA, normalisation using endogenous reference
genes represents relevant approach [3]. Reference genes
should ideally be constitutively expressed by all cell types
and should not be affected by disease and experimental
procedure. To date, a universal reference gene has not
been identified yet. Housekeeping genes (HKGs) are most
commonly used reference genes [1]. Although HKGs are
expressed by any cell, their expression varies among differ-
ent cell types/organs [8,9]. Use of HKGs as reference genes
for a particular sample type should be, therefore, vali-
dated.
So far, only few reference genes have been validated for
cells from respiratory compartment; specifically GNB2L1
was validated for bronchoalveolar macrophages in
patients with chronic obstructive pulmonary disease
(COPD) [10] and GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) for non-small cell lung cancer [11]. The
majority of studies published on qRT-PCR in lung setting
uses a general approach of normalisation against GAPDH
or ACTB (beta-actin) [12-16]. However, these "tradi-
tional" reference genes have been already found unsuita-
ble for normalising of mRNA levels in asthmatic airways
[17,18] and also for expression studies employing bron-
choalveolar macrophages [10].
In order to identify suitable reference genes for qRT-PCR
normalisation in the setting of bronchoalveolar compart-
ment, our aim, therefore, was to identify HKGs with the
most stable mRNA expression in bronchoalveolar (BAL)
cells. Our choice of candidate HKGs was based on 1) their
common use in previous qRT-PCR experiments (ACTB,
GAPDH, G6PD), 2) stable expression in different human
tissues in microarray experiments (ARF1, CANX, GPS1,
PSMB2, PSMD2) [8,9], and 3) stable expression in bron-
choalveolar macrophages and peripheral neutrophils
(GNB2L1, RPL32) [10,19]. To account for variations of
BAL cellular profile in different respiratory diseases, we
studied stability of HKGs mRNA expression in seventy-
one subjects across a spectrum of lung pathologies.
Besides BAL cellular profile and type of lung pathology,
four variables were investigated for their possible influ-
ence on mRNA expression of studied HKGs; these were:
smoking, gender, treatment, and age. Further, mRNA
expression stability of all ten HKGs was validated in the
second, independent BAL cohort consisting of seventeen
control subjects and sixty-three sarcoidosis patients with
special emphasis on patient subgroups. Finally, by inves-
tigation of mRNA expression of two cytokines known
associated with sarcoidosis, INFG (interferon gamma)
and CCL2/MCP-1, we provided practical evidence, that
normalisation with validated reference genes in clinical
samples is absolute prerequisite for obtaining clinically
unbiased valid information from qRT-PCR.
Methods
Subjects
BAL was performed according a standard procedure [20]
in 71 Caucasian subjects (1st cohort) with lung diseases
diagnosed between 2004 and 2006 in one referral centre
in the Czech Republic (Faculty Hospital Olomouc). The
diagnoses were in compliance with the criteria from the
International Statements/Standards of these diseases: 26
patients with interstitial lung diseases (sarcoidosis, idio-
pathic interstitial pneumonia, secondary fibrosis, asbesto-
sis, lipoproteinosis and silicosis), 19 cancer patients and
26 COPD patients. For clinical and laboratory characteris-
tics of studied subjects see Table E1 in the Additional file
2.
The subgroups based on gender (45 males/26 females),
smoking status (28 smokers/40 non-smokers), treatment
before BAL (24 untreated/47 treated), age (median age of
60 years as the division point; 36 patients >60 years/35
patients ≤ 60 years), and groups with normal (N)/patho-
logical (P) differential BAL cell counts were also analyzed.
The reference values for BAL cell counts (≥ 85% macro-
phages, ≤ 11% lymphocytes, <3% neutrophils, ≤ 1% eosi-
nophils) were based on our own laboratory values and
correspond to Meyer [21]. The subgroups according BAL
cell composition were as follows: 37 N/28 P macrophage-
, 46 N/19 P lymphocyte-, 48 N/17 P neutrophil- and 45
N/20 P eosinophil-counts.
The second cohort, used for validation of mRNA expres-
sion stability of studied HKGs, consisted of 80 subjects: 63
patients with pulmonary sarcoidosis and 17 control sub-
jects. The control group consisted of subjects (11 males, 6
females; 11 non-smokers, 5 smokers, 1 subject with
unknown smoking history; age 42.2 ± 15.7 yrs) undergo-
ing BAL within medical examination for "non-inflamma-
tory condition" e.g. psychogenic cough. All had normal
BAL fluid cytology, immunology, and microbiology &
CD4+/CD8+ ratio. For clinical and laboratory characteris-
tics of studied subjects from the second cohort see Table
E1 in the Additional file 2. None of the patients in the sec-BMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
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ond cohort received corticosteroid therapy before BAL.
The subgroups in the second cohort were based on gender
(37 males/43 females), smoking status (23 smokers/56
non-smokers), and presence of lung disease (63 sarcoido-
sis patients/17 control subjects). Further subgroups were
formed within the sarcoidosis patient group: based on the
presence/absence of Löfgren's syndrome (LS) (11 patients
with LS/52 patients without LS), involvement of paren-
chyma (17 patients with chest X-ray stage I/46 patients
with chest X-ray stages II and III), involvement of other
organs than lung (40 patients with only involvement of
lung/23 patients with multiorgan involvement) and
groups with normal (N)/pathological (P) differential BAL
cell counts. The subgroups according BAL cell composi-
tion were as follows: 15 N/48 P macrophage-, 14 N/49 P
lymphocyte-, 56 N/7 P neutrophil- and 58 N/5 P eosi-
nophil-counts.
The study was approved by the Ethics Committee of the
Medical Faculty Palacky University & Faculty Hospital
Olomouc. All subjects signed informed consent about
usage of an aliquot of BAL sample, taken primarily for
diagnostic purposes, also for the research purposes of this
study.
BAL sample processing
BAL cells (0.5–1.5 × 106) were separated from the BAL
fluid and washed as previously described [22]. Briefly,
BAL samples were filtered through one gauze layer fol-
lowed by separation of BAL cells by centrifugation (400 g,
4°C). The cells were washed twice with 10 ml ice-cold
PBS-DEPC, counted and resolved in 50 μl PBS-DEPC.
After immediate addition of RNAlater (300 μl; Ambion,
Austin, TX, USA), the cells were stored at 4°C overnight
and then at -20°C until use. The time between BAL proce-
dure and processing of sample did not exceeded 2 hours.
Total RNA isolation and quality assessment, reverse 
transcription
The cells stored in RNAlater were recovered by centrifuga-
tion (4000 g, 4°C, 45 min) after 1:2 dilution with ice-cold
PBS-DEPC as recommended by the manufacturer. Total
RNA was isolated using mirVana miRNA kit (Ambion)
and genomic DNA was eliminated by TurboDNAfree kit
(Ambion) according to the manufacturer's recommenda-
tion. The quantity and quality of RNA samples were
assessed by 2100 Bioanalyzer (Agilent Technologies, Palo
Alto, USA) using RNA 6000 Nano assays.
Reverse transcription (0.5 μg total RNA, total volume of
20 μl) was performed with Reverse-iT RTase Blend using
anchored dT primers (0.4 μg; ABgene, Epsum, U.K.) at
47°C for 45 min in triplicates and then combined. All
cDNA samples were diluted to 4 ng input total RNA/μl
and stored in aliquots at -20°C until use.
Gene expression measurements by qRT-PCR
Fluorescently labelled Locked Nucleic Acid probes (LNA,
Universal ProbeLibrary; Roche Applied Science, Indianap-
olis, USA) and the primers (Metabion, Munich, Germany)
for investigated genes (Table 1) were selected using Probe-
Finder assay design tool http://www.universal
probelibrary.com (Table 2). PCR reaction mixes were pre-
pared as follows: equal amount of cDNA (5 μl, corre-
sponding to 20 ng calculated on input total RNA) for each
individual gene was added to 20 μl PCR-Mix (ABgene).
The final concentrations were 900 nM each sense and
antisense primers, 100 nM LNA probe, 3.5 mM MgCl2,
200 μM each dNTPs, 1 U Thermo-Start TAQ polymerase,
1× Thermo-Start Buffer (ABgene). After initial denatura-
tion (one cycle at 94°C for 15 min), 40 cycles amplifica-
tion (94°C for 45 s, 60°C for 30 s) were performed on
Table 1: Description of investigated genes.
Gene abbreviation Gene name (synonyms) GenBank* Accession number Function
ACTB actin, beta NM_001101.2 Cytoskeletal structural protein
ARF1 ADP-ribosylation factor 1 NM_001658.3 Activator of phospholipase D
CANX calnexin NM_001746.3 Molecular chaperone
G6PD glucose-6-phosphate dehydrogenase X03674.1 NADPH production
GAPDH glyceraldehyde-3-phosphate dehydrogenase NM_002046.3 Glycolysis enzyme
GNB2L1 Homo sapiens guanine nucleotide binding 
protein (G protein), beta polypeptide 2-like 1
NM_006098.4 Receptor for activated C-kinase
GPS1 G protein pathway suppressor 1 U20285.2 G protein suppressor
PSMB2 proteasome (prosome, macropain) subunit, 
beta type, 2
NM_002794.3 Peptide cleavage
PSMD2 26S proteasome subunit p97 D78151.1 Peptide cleavage
RPL32 ribosomal protein L32, transcript variant 1 NM_000994.3 Member of 80 different ribosome 
proteins
INFG interferon gamma NM_000619.2 Cytokine
CCL2 CC chemokine ligand-2/MCP-1 NM_002982.3 Chemotactic cytokine
*Gene sequences available online at http://www.ncbi.nlm.nih.gov/BMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
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RotorGene 3000 system (Corbett Research, Sydney, Aus-
tralia).
Relative expression was calculated using second derivative
method (Additional file 3) (RotorGene Software 6.1.71,
Corbett Research) as follows: Expression = average ampli-
fication(CTtcalibrator-CTtsample). cDNA from human universal
reference RNA (Stratagene, La Jolla, CA, USA) was used as
calibrator (in quadruplicates) at concentration of 1.25 ng/
reaction calculated on input RNA. For definition of the
second derivative method, Takeoff point (CTt) and aver-
age amplification see Additional file 3.
Statistical analysis
Descriptive statistics, F-test for CTt variance equality, Kol-
mogorov-Smirnov test for normality of log-transformed
relative expression values were calculated by software
SPSS 13.0 (SPSS Inc, Chicago, IL, USA). Log-transformed
relative expression values for INFG and CCL2 were used
for statistical calculations by Student's t-test, one-way
ANOVA. P < 0.05 was considered significant. Equivalence
test [23,24], statistical applets BestKeeper [25], geNorm
[26] and NormFinder [27] were used for the analysis of
gene expression stability. Normalisation factors (NF) for
genes and gene pairs were calculated according to Vande-
sompele et al [26]. For more details on statistical
approaches and calculation of normalisation factor see
the Additional file 1.
Results
Quality of RNA isolated from BAL samples
All investigated RNA samples were of good quality, mean
RIN (RNA Integrity Number) values (± S.D.) were 7.4 ±
1.0 (range from 5.5 to 8.6). Among all samples, ratios
28S:18S varied between 1.0–1.4 with no visible degrada-
tion products (Fig. E1 in Additional file 4).
Table 2: Characteristics of used primers; LNA probes and amplicon sizes in reverse transcriptase-polymerase chain reaction reaction.
Gene abbreviation Amplicon size (basepairs) Sense, antisense primers LNA probe¥
ACTB 76 5'-attggcaatgagcggttc-3'
5'-ggatgccacaggactccat-3'
#11
ARF1 70 5'-gccactacttccagaacacaca-3'
5'-tcgttcacacgctctctgtc-3'
#56
CANX 108 5'-aacaccagaactcaacctgga-3'
5'-tgtcggaagatgaagtgcag-3'
#55
G6PD 75 5'-ctggtggccatggagaag-3'
5'-gcatttcaacaccttgacctt-3'
#22
GAPDH 78 5'-tccactggcgtcttcacc-3'
5'-ggcagagatgatgaccctttt-3'
#45
GNB2L1 72 5'-gctactaccccgcagttcc-3'
5'-cagtttccacatgatgatggtc-3'
#55
GPS1 66 5'-gcaaccagatccatgtcaagt-3'
5'-tgttggctggagtcagctc-3'
#36
PSMB2 72 5'-agagggcagtggaactcctt-3'
5'-aggttggcagattcaggatg-3'
#50
PSMD2 68 5'-gcctcacccagattgacaag-3'
5'-ggcaagaagagctcctgactta-3'
#82
RPL32 75 5'-gaagttcctggtccacaacg-3'
5'-gcgatctcggcacagtaag-3'
#17
INFG 112 5'-ggcattttgaagaattggaaag-3'
5'-tttggatgctctggtcatctt-3'
#21
CCL2 93 5'-agtctctgccgcccttct-3'
5'-gtgactggggcattgattg-3'
#40
¥Numbers of LNA probes according to the commercially available library http://www.universalprobelibrary.comBMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
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Amplification efficiency and reproducibility of qRT-PCR 
with fluorescently labelled LNA-probes
In order to determine the amplification efficiency for all
studied genes, 5-point standard curves with known con-
centrations of transcribed human universal reference RNA
were constructed. The amplification efficiencies of LNA-
based qRT-PCR for studied HKGs varied between 95 to
100%, except for ARF1 where the amplification efficiency
of 85% was achieved. The linear regression coefficient
(R2) for all ten genes ranged between 0.998–0.999. Based
on 16 replicates, intra-assay variation of less than 0.7%
and inter-assay variation of less than 1.6% were achieved.
Negative controls using not transcribed RNA samples for
all genes were negative.
Gene expression levels of ten housekeeping genes within 
the whole 1st cohort sample set
In order to evaluate gene expression levels of all studied
HKGs within the whole patient sample set of the 1st
cohort, mRNA expressions for every gene were measured
in individual BAL samples. Gene expression levels in indi-
vidual samples showed a broad range of variance between
CTt 13.1 (for GAPDH) and CTt 29.20 (for PSMD2) (Fig.
1). Out of ten studied genes, ACTB (mean CTt 17.92) and
RPL32 (mean CTt 18.65) were expressed at the highest
levels; PSMD2 (mean CTt 25.55) and GPS1 (mean CTt
24.86) at the lowest levels in BAL cells. The lowest expres-
sion variability within all samples was observed for the
gene PSMB2 (mean CTt ± SD, 23.66 ± 0.86) and RPL32
(18.65 ± 0.92). Genes PSMD2 (25.55 ± 1.67) and
GNB2L1 (21.97 ± 1.54) showed the most variable expres-
sion within the sample set. F-test showed that PSMB2 and
RPL32 had significantly lower variance of CTt values
when compared to CANX, GNB2L1, ACTB, PSMD2,
ARF1, GPS1, G6PD and GAPDH (p < 0.02). Descriptive
statistics of gene expression data and corresponding abso-
lute x-fold change values for all studied genes calculated
by the applet Bestkeeper are shown in Table 3.
Analysis of expression stability of ten HKGs in BAL cells 
from the 1st patient cohort by equivalence test and 
statistical applets Bestkeeper, geNorm and NormFinder
In order to find out the most suitable reference genes for
normalisation of gene expression in BAL cells, four differ-
ent statistical approaches (equivalence test, applets Best-
keeper, geNorm and NormFinder) were applied in
parallel to assess the gene expression stability of ten HKGs
within the whole sample set and also in patient subgroups
based on gender, smoking status, treatment, disease type,
age, and BAL differential cell counts.
a) Equivalence test
In order to identify the most stably expressed genes in
patient subgroups by equivalence test, we applied two-
fold expression change cut-off for group-wise compari-
sons. Genes GAPDH and PSMD2 were identified as the
least stably expressed genes in BAL samples, equivalently
expressed only in subgroups according gender and age
(Fig. 2, data for age comparison not shown). Genes ARF1,
ACTB, CANX, GAPDH, GNB2L1, G6PD, GPS1, PSMD2
were found not equivalently expressed in more than two
of eight studied subgroups. Out of all studied genes, only
PSMB2 and RPL32 were found equivalently expressed in
all studied subgroups (Fig. 2). The comparison of results
of equivalence tests for two most stable genes (PSMB2,
RPL32) and two "traditional" reference genes (ACTB,
GAPDH) in all subgroups is shown in Fig. 3.
b) Analysis by BestKeeper
Analysis by the applet BestKeeper showed that only two
genes (PSMB2 and RPL32) are stably expressed within the
whole data set (Table 3), as well as in all studied sub-
groups based on gender, smoking status, treatment, type
of the disease, age and BAL cellular composition (data not
shown). The expression of genes ACTB, ARF1, CANX,
GAPDH, G6PD, GPS1, GNB2L1 and PSMD2 has to be
considered as inconsistent (standard deviation of the CTt
value > 1), thus they were excluded from further analysis.
When the regression analysis was performed with two sta-
ble genes, the PSMB2 was shown to be more suitable as a
reference gene (coefficient of correlation, r = 0.914; p =
0.001) than RPL32 (r = 0.865; p = 0.001).
Expression levels of ten housekeeping genes in bronchoalve- olar cells from the 1st cohort Figure 1
Expression levels of ten housekeeping genes in bron-
choalveolar cells from the 1st cohort. Expression levels 
of ten HKGs in CTt values over all BAL samples (n = 71). 
The data are expressed as whisker box plots; the box repre-
sents the 25th–75th percentiles, the median is indicated by a 
bar across the box, the whiskers on each box represent the 
minimum and maximum values.BMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
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c) Analysis by geNorm
Average expression stability measure of ten HKGs in the
whole sample group during stepwise exclusion of the least
stable genes by the applet geNorm resulted in following
gene order: the most stable-ACTB-GPS1-GNB2L1-ARF1-
PSMB2-RPL32-CANX-G6PD-PSMD2-GAPDH-the least
stable. When the applet was applied to particular sub-
groups, we obtained various ranking lists of suitable refer-
ence genes for various subgroups: e.g. ACTB and GNB2L1
were the most stable genes for smokers and ACTB and
PSMB2 for non-smokers; PSMB2 and RPL32 were the
most stable genes for males and ACTB and GNB2L1 for
females.
d) Analysis by NormFinder
Analysis by the applet NormFinder ranked ten genes
according their expression stability in the whole patient
set in the following order: the most stable-ACTB-PSMB2-
GNB2L1-ARF1-GPS1-RPL32-CANX-G6PD PSMD2-
GAPDH-the least stable. However, we obtained various
ranking lists when we calculated the expression stability of
ten investigated HKGs in subgroups: e.g. genes PSMB2
and ARF1 were the most stable genes in subgroups based
on smoking status (smokers vs. non-smokers), ACTB and
GNB2L1 were the most stable genes in subgroups based
on gender (males vs. females).
Validation of expression stability of ten HKGs in BAL cells 
from the 2nd patient cohort by equivalence test
In order to confirm that PSMB2 and RPL32 genes, identi-
fied as the most stable genes in the aforementioned anal-
yses in the 1st cohort, has indeed the most stable mRNA
expression unaffected by range of tested variables, we
investigated gene expression of all ten genes in the second,
independent BAL cohort (63 patients with pulmonary sar-
coidosis and 17 control subjects) by equivalence test. The
relative gene expression values for all genes were com-
pared among the patient subgroups based on gender,
smoking status, and clinical characteristics such as pres-
ence of disease, presence of Löfgren's syndrome, involve-
ment of parenchyma, involvement of other organs than
lung and BAL differential cell counts (Fig. 4, Fig. E2 in
Additional file 5). Out of ten studied genes, only PSMB2
and RPL32 genes were equivalently expressed in all tested
subgroups of the second cohort.
Assessment on the minimal number of reference genes for 
normalisation of qRT-PCR in BAL cells
In order to evaluate the minimal number of reference
genes for normalisation of qRT-PCR in BAL cells, we cal-
culated the normalisation factors for novel reference
genes and their combination (PSMB2, RPL32, PSMB2-
RPL32) and for the "traditional" reference genes in lung
Table 3: Descriptive and correlation analysis for ten housekeeping genes in the 1st cohort obtained by BestKeeper statistical applet.
RPL32* GAPDH ACTB GPS1 ARF1
GM [CTt] 18.65 20.44 17.92 24.86 22.15
AM [CTt] 18.69 20.53 17.99 24.91 22.20
Min [CTt] 15.90 13.10 14.30 22.20 18.80
Max [CTt] 22.00 24.60 21.60 28.50 25.60
SD [± CTt] 0.92 1.34 1.21 1.24 1.14
CV [% CTt] 4.93 6.51 6.73 4.99 5.12
Min [x-fold] -6.73 -161.54 -12.31 -6.34 -10.21
Max [x-fold] 10.19 17.93 12.80 12.43 10.92
SD [± x-fold] 1.89 2.53 2.31 2.37 2.20
PSMD2 G6PD GNB2L1 CANX PSMB2*
GM [CTt] 25.55 24.36 21.97 24.42 18.65
AM [CTt] 25.63 24.42 22.05 24.48 18.69
Min [CTt] 21.40 20.90 17.60 20.50 15.90
Max [CTt] 29.20 28.40 25.50 28.30 22.00
SD [± CTt] 1.67 1.34 1.54 1.25 0.92
CV [% CTt] 6.51 5.48 7.00 5.10 4.93
Min [x-fold] -17.81 -11.03 -20.63 -15.17 -6.73
Max [x-fold] 12.51 16.42 11.58 14.69 10.19
SD [± x-fold] 3.18 2.53 2.91 2.38 1.89
Definition of abbreviations: GM [CTt], geometric mean of CTt; AM [CTt], arithmetic mean of CTt; Min [CTt] and Max [CTt], minimum and 
maximum values of CTt; SD [± CTt], standard deviation of the CTt; CV [%CTt], coefficient of variance expressed as a percentage on the CTt level. 
Min [x-fold] and Max [x-fold]: the extreme values of expression levels expressed as an absolute x-fold over- or under- regulation coefficient; SD [± 
x-fold]: standard deviation of the absolute regulation coefficients.
* Stably expressed genes were selected according to the criteria (SD [± CTt] < 1) published in Pfaffl et al [25].BMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
Page 7 of 14
(page number not for citation purposes)
Figure 2
Equivalence test for ten housekeeping genes in the 1st cohort subgroups based on the type of lung disease, 
treatment, smoking status, gender, and bronchoalveolar lavage cellular composition. Differences of the means (u) 
and matching symmetrical confidence intervals (-) are shown for the log2-transformed relative expression of HKGs. Y-axis rep-
resents the fold change in expression among subgroups. The deviation area [-1; 1] for a fold change ≤ 2 lies within the dashed 
lines. If the symmetrical confidence interval is a part of the deviation area and contains zero in them, the gene is considered to 
be expressed equivalently. For more details on calculation see the Additional files and for statistical methodology the refer-
ences [23,24]. Mean differences were calculated as follows: Mean(interstitial diseases)-Mean(other lung diseases), 
Mean(treated)-Mean(untreated), Mean(males)-Mean(females), Mean(smokers)-Mean(non-smokers), and Mean(pathological 
BAL cell counts)-Mean(normal BAL cell counts) for macrophages, lymphocytes, neutrophils and eosinophils. Reference BAL 
cell counts were based on own laboratory values and correspond to Meyer [21], for more details see Methods section.
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settings (ACTB, GAPDH) in all individual samples in both
cohorts separately. Generally, the most suitable reference
genes are the genes with mean NF value closest to 1 and
with the lowest SD. Gene PSMB2 alone showed the lowest
mean NF, SD and coefficient of variation (CV) in both
cohorts (1. cohort: mean NF ± SD, CV: 1.27 ± 0.89, 70%;
2. cohort: 1.17 ± 0.63, 54%). Gene RPL32 alone showed
in both cohorts the same mean NF as PSMB2 gene, but
higher SD and CV (1. cohort: 1.27 ± 0.93, 73%; 2. cohort:
1.17 ± 0.71, 61%). Pairing of PSMB2 with RPL32 did not
significantly improve the mean NF value and the variabil-
ity (1. cohort: 1.29 ± 0.91, 72%; 2. cohort: 1.14 ± 0.59,
52%) compared to PSMB2 or RPL32 alone. Genes ACTB
(1. cohort: 1.64 ± 1.52, 93%; 2. cohort: 1.20 ± 0.75, 63%)
and GAPDH (1. cohort: 1.60 ± 2.98, 186%; 2. cohort: 1.22
± 0.76, 62%) were found less suitable as reference genes
for BAL cells. We, therefore, recommend single genes
PSMB2 and RPL32 as denominators for gene expression
studies in BAL cells.
Effect of the used reference gene on relative target gene 
expression values: study of mRNA expression of INFG and 
CCL2 known to be associated with pulmonary sarcoidosis 
(2. cohort)
In order to demonstrate the effect of used reference genes
on the result of target gene expression data in BAL cells, we
investigated relative mRNA expression of two cytokines
known to be associated with sarcoidosis, INFG and CCL2,
in sarcoidosis patients and control subjects (2nd cohort).
The following genes were applied as denominators: 1) ref-
erence genes validated in our study (PSMB2, RPL32) and
2) "traditional" reference genes (ACTB, GAPDH). The
data are presented as a mean fold change of relative
expression compared to control subjects (normalized to
1).
Relative mRNA expression levels of INFG were higher in
sarcoidosis patients than in control subjects when the nor-
malisation was done with gene PSMB2 (fold change ± SD:
2.56 ± 1.62; p = 0.004), with gene RPL32 (2.58 ± 1.46; p =
0.004), and with gene pair PSMB2-RPL32 (2.44 ± 1.20; p
= 0.02) (Fig. 5). When the expression level of INFG was
normalised to ACTB (2.42 ± 1.71; p = 0.053) or to GAPDH
(1.95 ± 1.48; p = 0.09), the mRNA expression of INFG did
Comparison of results of equivalence tests in all studied subgroups of the 1st cohort for two most stable genes PSMB2 (the left  upper part) and RPL32 (the left lower part) and two most commonly used genes ACTB (the right upper part) and GAPDH  (the right lower part) in bronchoalveolar (BAL) cells Figure 3
Comparison of results of equivalence tests in all studied subgroups of the 1st cohort for two most stable genes 
PSMB2 (the left upper part) and RPL32 (the left lower part) and two most commonly used genes ACTB (the 
right upper part) and GAPDH (the right lower part) in bronchoalveolar (BAL) cells. 1 – Type of lung disease; 2 – 
Treatment; 3 – Smoking status; 4 – Gender; 5 – BAL Macrophage count; 6 – BAL Lymphocyte count; 7 – BAL Neutrophil 
count; 8 – BAL Eosinophil count. For more details see the legend to Fig. 2.
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Figure 4
Equivalence test for ten housekeeping genes in the 2nd cohort subgroups based on the presence of disease, 
involvement of parenchyma, presence of Löfgren's syndrome, multi-organ involvement, smoking status, gen-
der, and bronchoalveolar lavage cellular composition. Mean differences were calculated as follows: Mean(sarcoidosis 
patients)-Mean(control subjects), Mean(patients with involvement of parenchyma: CXR stages II/III)-Mean(patients without 
involvement of parenchyma: CXR stage I), Mean(Löfgren's syndrome patients)-Mean(non-Löfgren's syndrome patients), 
Mean(multi-organ involvement)-Mean(involvement of lung only), Mean(smokers)-Mean(non-smokers), Mean(males)-
Mean(females), and Mean(pathological BAL cell count)-Mean(normal BAL cell count) for macrophages, lymphocytes, neu-
trophils and eosinophils. For more details see the legend to Fig. 2.BMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
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Comparison between the relative mRNA expression (ratio target gene/reference gene) of INFG gene (the upper part) and  CCL2 gene (the lower part) in unseparated bronchoalveolar cells of sarcoidosis patients (S, n = 63) and control subjects (C, n  = 17) from the 2nd cohort using newly validated (PSMB2/RPL32) and "traditional" reference genes (ACTB/GAPDH) as denom- inators Figure 5
Comparison between the relative mRNA expression (ratio target gene/reference gene) of INFG gene (the 
upper part) and CCL2 gene (the lower part) in unseparated bronchoalveolar cells of sarcoidosis patients (S, n 
= 63) and control subjects (C, n = 17) from the 2nd cohort using newly validated (PSMB2/RPL32) and "tradi-
tional" reference genes (ACTB/GAPDH) as denominators. The data are presented as a mean fold change of relative 
expression compared to control subjects (normalized to 1); the whiskers on each box represent the SD values. For details see 
Methods section Gene expression measurements by qRT-PCR. *p < 0.05.BMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
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not differ between control subjects and sarcoidosis
patients (Fig. 5).
Similar, when CCL2 mRNA levels were expressed as a
ratio to ACTB (1.00 ± 0.85; p = 0.46) or to GAPDH (1.37
± 0.98; p = 0.43), there were not significant differences in
mRNA levels in BAL cells between sarcoidosis patients
with chest radiographic stage 2 and stage 1 patients. Using
genes PSMB2 (1.95 ± 1.66; p = 0.02) and gene RPL32
(1.77 ± 1.25; p = 0.03), and gene pair PSMB2-RPL32 (1.65
± 1.17; p = 0.02) as denominators, CCL2 mRNA levels dif-
fered between chest radiographic stage 2 and stage 1 sar-
coidosis patients (Fig. 5).
Discussion
Aiming at finding suitable reference genes for quantitative
gene expression profiling studies in bronchoalveolar cells,
we have investigated the gene expression of ten house-
keeping genes selected according their expression stability
reported in literature or their common use in qRT-PCR.
Out of these, two genes PSMB2 and RPL32 were found
constantly expressed in unseparated BAL cells from sev-
enty-one subjects irrespective of lung pathology, smoking
status, gender, treatment, age and BAL cellular composi-
tion. The stability of mRNA expression of PSMB2 and
RPL32 genes was further validated in the second, inde-
pendent BAL cohort of sixty-three sarcoidosis patients and
seventeen control subjects. By contrast to PSMB2 and
RPL32, expression levels of genes ACTB, ARF1, CANX,
GAPDH, G6PD, GPS1, GNB2L1 and PSMD2 considerably
varied among studied patient subgroups in both investi-
gated cohorts thus making these genes less suitable for the
normalisation in qRT-PCR. We, therefore, recommend
PSMB2 and RPL32 as suitable reference genes for the nor-
malisation of the gene expression in unseparated BAL
cells, namely in interstitial lung diseases. Moreover, based
on our data, PSMB2 and RPL32 represent promising can-
didate reference genes for other lung pathologies such as
COPD and cancer. Finally, we demonstrated on the exam-
ple of INFG and CCL2 mRNA expression in sarcoidosis
that the normalisation with validated reference genes in
clinical samples is absolute prerequisite for obtaining
clinically meaningful information from qRT-PCR.
Although qRT-PCR is an established method for quantify-
ing of mRNA expression in BAL samples, normalisation
for differences among individual samples is the major dif-
ficulty of this methodology [1,7]. Several normalisation
strategies can be applied: normalisation to sample vol-
ume, to total RNA and to internal reference genes or their
combination. Normalisation to equal volumes on its own
is not suitable for respiratory settings because BAL sam-
ples differ in cell counts and cellular composition. The
other approach, the normalisation for quantity of total
RNA, is disqualified because it does not correct for differ-
ences in RNA quality and in reverse transcriptase efficien-
cies among samples [28]. Nowadays, the endogenous
reference genes represent the most suitable and easiest
way for normalisation of clinical samples in qRT-PCR
[1,29-32]. Moreover, reference genes may correct also for
differences in RNA integrity among the samples [33,34].
Similarly to Huggett et al [3], we affirm that the combina-
tion of similar sample size, similar RNA concentration in
reverse transcription and use of validated reference genes
represents the proper normalisation strategy for BAL sam-
ples.
Although it is known that the normalisation with unsuit-
able reference gene may lead to misinterpretation of target
genes expression data [17,35], most investigators have
generally used the genes GAPDH and ACTB as reference
genes to normalize qRT-PCR in lung settings without pre-
vious validation [12-16]. The reason may be the fact that
the known approaches for validation of reference gene
stability have been introduced mainly for cell cultures and
tissues [2,26,27,36] and no general approach for valida-
tion of reference genes in clinical samples is recom-
mended nowadays. In our study, we applied four different
mathematical and statistical models to select stably
expressed HKGs genes in BAL samples. Similarly to Rob-
inson et al [37], we observed that the output of the most
suitable reference genes using pair-wise approach geNorm
[26] is influenced by chosen set of candidate genes, and
the ranking of the genes occurs according the similarity in
expression profiles [27]. Another applet, the model-based
approach NormFinder [27], takes already into account the
individual gene expression variability and calculates the
gene expression stability in subgroups. By contrast to
Andersen et al [27], who compared gene expression in
two types of cancer tissues, we aimed to investigate the
influence of many variables (e.g. gender, smoking, age,
BAL cellular composition, lung pathology and treatment)
on the expression stability of studied genes. Doing so, we
obtained various ranking lists of suitable reference genes
for various subgroups, thus making NormFinder
approach less suitable for our purpose. Using the third
used approach, the BestKeeper applet, only PSMB2 and
RPL32 were revealed as stably expressed genes in BAL
samples, the eight remaining genes were excluded from
further analyses as inconsistently expressed [25]. Moreo-
ver, the limitation of this approach is the use of Pearson's
correlation [25], which makes it unsuitable for analyses of
non-normally distributed data commonly observed in
clinical sample sets. The heterogeneity of the results
obtained by the statistical applet Bestkeeper, geNorm and
NormFinder and also having in mind our aim to identify
genes stably expressed irrespective of many variables (gen-
der, smoking, BAL cellular composition, lung pathology
and medication) contributed to our final decision to
apply equivalence test into our analyses of HKGs expres-BMC Molecular Biology 2008, 9:69 http://www.biomedcentral.com/1471-2199/9/69
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sion stability in BAL cells. Doing so, to exclude genes with
high expression variability within the sample set and stud-
ied subgroups, we set very strict criteria corresponding to
two-fold change in gene expression [24]. Similarly to pre-
vious reports [10,17] we observed that "traditional" refer-
ence genes like ACTB and GAPDH are indeed unsuitable
for normalisation of gene expression in BAL cells. Even in
the case of GNB2L1, gene recommended as a reference
gene for BAL macrophages from COPD patients [10], we
observed that its expression in BAL cells is influenced by
lung pathology, treatment and by eosinophil and neu-
trophil counts in BAL samples. Only two genes, PSMB2
and RPL32, were found constantly expressed in all studied
subgroups irrespective of smoking, gender, treatment, age,
lung pathology and BAL cellular composition. To enhance
the evidence about invariable expression of PSMB2 and
RPL32 genes, their expression was further validated in sec-
ond, independent BAL cohort of patients with sarcoidosis
and control subjects. We are aware that we dealt mostly
with bronchoalveolar cells from interstitial lung diseases
and sample sizes of other diseases have been limited.
Addressing this limitation in the future is prerequisite for
definite conclusion about general usage of PSMB2 and
RPL32 as reference genes for expression studies in lung
compartment as a whole.
PSMB2 belongs to the group of genes encoding for consti-
tutively expressed 20S proteasomal core subunits, RPL32
is a gene encoding for a component of the 60S ribosomal
subunit. Various ribosomal proteins have been already
validated for qRT-PCR: RPL13A for the pancreas and the
prostate tissues [38], LRP10 for adipose tissue [39], RPL32
for human neutrophils [19] and BAL macrophages from
COPD patients, where it was stable irrespective of disease
severity [10]. PSMB2 showed only 29% variation in
expression among 19 human tissues by microarray tech-
nique [8] and here we show for the first time its suitability
as a reference gene for qRT-PCR also in unsepared BAL
cells.
There has been ongoing discussion about the minimal
number of reference genes required for qRT-PCR in clini-
cal samples. Although the combination of more than one
normalisation gene resulted in improved accuracy in sev-
eral studies [26,27,40-42], other investigators showed
that normalisation with a single gene is sufficient for most
research applications [36,43-45]. Also our analyses
showed that the combination of two most stable genes
(PSMB2 and RPL32) did not yield improved precision
over normalisation with PSMB2 or RPL32 genes alone.
We, therefore, suggest that the use of single reference
genes PSMB2 or RPL32 is sufficient for normalisation of
target gene expression in BAL cells, at least in interstitial
lung diseases, where we validated their expression stabil-
ity in the second, independent BAL cohort. PSMB2 gene is
a moderate-copy gene, thus can better control for RNA
isolation efficiency, RNA quality and RT-efficiency than
RPL32 expressed at high abundance.
In order to demonstrate that the normalisation with refer-
ence genes with variable expression may indeed lead to
the misinterpretation of target gene expression and even
to missing the identification of clinically relevant mole-
cules, we applied the newly defined reference genes for
investigation of mRNA levels of two cytokine genes
reported to be associated with sarcoidosis. These were:
Th1 cytokine INFG, which mRNA and protein was ele-
vated in Th1 polarised sarcoidosis [46,47] and CC chem-
okine ligand (CCL)-2/MCP-1, implicated in the
development of sarcoid alveolitis namely in chest X-ray
stage 2 disease [22]. In our patients, increase of INFG
mRNA in sarcoid BAL cells was observed only when
PSMB2/RPL32 were used as denominators in the normal-
ization procedure. Controversially, normalization of
INFG transcripts to ACTB/GAPDH did not resulted in
INFG mRNA up-regulation. Similarly, CCL2 mRNA up-
regulation in sarcoid chest X-ray stage 2 disease was
observed when stably expressed reference genes PSMB2/
RPL32 were used. Use of ACTB/GAPDH as denominators
again yielded inconclusive, ambiguous expression data.
By these reports we emphasize that our results provide an
important and clear message for pulmonary science
because only using validated (i.e. stably expressed) refer-
ence genes for normalization will one ensure that detected
changes in target gene expressions in BAL samples are
valid and therefore clinically meaningful. By contrast,
usage of genes with variable expression such as ACTB or
GAPDH for normalization leads to misinterpretation of
target gene expression in lung samples.
Conclusion
In conclusion, our study aimed at identifying stable genes,
the expression of which is not influenced by variables
such as smoking, gender, age, lung pathology, treatment
and BAL cellular composition. Genes PSMB2 and RPL32
fulfilled the above criteria, and, therefore, they represent
suitable normalisation genes for qRT-PCR in bronchoal-
veolar cells, namely for studies in sarcoidosis and other
interstitial lung diseases.
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